CA IX-IN-1
CA IX-IN-1 (compound 12g) is an effective and selective inhibitor of hCA IX with IC50 value of 7 nM. CA IX-IN-1 exhibits antitumor activity.
For research use only. We do not sell to patients.
- Formula: C16H22N4O8S
- Molecular Weight:430.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
CA IX-IN-1 (compound 12g) displays effective inhibition against hCA I, hCA II and hCA IX with IC50 values of 4, 0.018, 0.007 μM, respectively[1].
CA IX-IN-1 (compound 12g) (0.1 μM, 72 hours; HT-29 and MDA-MB-231 cells) exerts the potent antitumor activities against human cancer cell lines[1].
CA IX-IN-1 (compound 12g) (0-1 mM, 48 hours; HT-29 and MDA-MB-231 cells) induces highly expression level and enzyme activity of HCA IX in tumor cells with enhance the acidification of extracellular pH[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-29 (colon carcinoma cells) and MDA-MB-231 (breast cancer cells)
-
Concentration:0.1 mM
-
Incubation Time:72 hours
-
Result:Revealed antitumor activity against HT-29 and MDA-MB-231 (IC50 = 32 and 31 μM respectively).
-
Cell Line:MDA-MB-231 (breast cancer cells)
-
Concentration:0.1 μM
-
Incubation Time:72 hours
-
Result:Decreased (20–35%) of IC50 values were detected compared with that obtained for DOX alone.
Chemical Information
-
Molecular Weight 430.43
-
Formula C16H22N4O8S
-
SMILES
CO[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CN2C=C(N=N2)COC3=CC=CC(S(N)(=O)=O)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)